Loading…
Lobbying Spend
—
Filings
4
Firms Hired
1
Active Period
2022
Client-reported lobbying expenses on LDA filings
Lobbying firms retained by this client; amounts are client-reported expenses when available
Government entities explicitly identified as targets in LDA filings
Most frequently reported lobbying issues
Bill numbers found in source-reported LDA specific issue text; broad topic matches are excluded
Consolidated Appropriations Act, 2023
2022 · fourth_quarter · Firm: TRESS CAPITOL ADVISORS
Opposition to provision in FDA User Fee Reauthorization that bans certain medical devices. H.R. 7667 / S. 4348, Food and Drug Amendments of 2022 and provision in Consolidated Appropriations Act, 2023, H.R.2617.
Client expense: — · Firm income: $30,000
Matched citations: H.R.2617
Food and Drug Amendments of 2022
2022 · fourth_quarter · Firm: TRESS CAPITOL ADVISORS
Opposition to provision in FDA User Fee Reauthorization that bans certain medical devices. H.R. 7667 / S. 4348, Food and Drug Amendments of 2022 and provision in Consolidated Appropriations Act, 2023, H.R.2617.
Client expense: — · Firm income: $30,000
Matched citations: H.R. 7667
Opposition to provision in FDA User Fee Reauthorization that bans certain medical devices. H.R. 7667 / S. 4348, Food and Drug Amendments of 2022 and provision in Consolidated Appropriations Act, 2023, H.R.2617.
Client expense: — · Firm income: $30,000
Matched citations: S. 4348
Consolidated Appropriations Act, 2023
2022 · fourth_quarter · Firm: TRESS CAPITOL ADVISORS
Opposition to provision in FDA User Fee Reauthorization that bans certain medical devices. H.R. 7667 / S. 4348, Food and Drug Amendments of 2022 and provision in Consolidated Appropriations Act, 2023, H.R.2617.
Client expense: — · Firm income: $30,000
Matched citations: H.R.2617
Food and Drug Amendments of 2022
2022 · fourth_quarter · Firm: TRESS CAPITOL ADVISORS
Opposition to provision in FDA User Fee Reauthorization that bans certain medical devices. H.R. 7667 / S. 4348, Food and Drug Amendments of 2022 and provision in Consolidated Appropriations Act, 2023, H.R.2617.
Client expense: — · Firm income: $30,000
Matched citations: H.R. 7667
Opposition to provision in FDA User Fee Reauthorization that bans certain medical devices. H.R. 7667 / S. 4348, Food and Drug Amendments of 2022 and provision in Consolidated Appropriations Act, 2023, H.R.2617.
Client expense: — · Firm income: $30,000
Matched citations: S. 4348
Food and Drug Amendments of 2022
2022 · third_quarter · Firm: TRESS CAPITOL ADVISORS
Opposition to provision in FDA User Fee Reauthorization that bans certain medical devices. H.R. 7667 / S. 4348, Food and Drug Amendments of 2022.
Client expense: — · Firm income: —
Matched citations: H.R. 7667
Opposition to provision in FDA User Fee Reauthorization that bans certain medical devices. H.R. 7667 / S. 4348, Food and Drug Amendments of 2022.
Client expense: — · Firm income: —
Matched citations: S. 4348
Source: Senate LDA